Literature DB >> 31999849

The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions.

Catherine Atkin1, Vinay Reddy-Kolanu2, Mark T Drayson3, Elizabeth Sapey1, Alex G Richter3.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) affects 3·2% of adults aged >50 years. MGUS carries a life-long risk of progression to multiple myeloma and causes complications including infection and renal impairment; common causes of hospital admission. This study aimed to assess MGUS prevalence in emergency medical hospital admissions. Patients were recruited from unselected emergency medical admissions in a hospital in the United Kingdom. Serum protein electrophoresis was performed, with immunofixation of abnormal results. Reason for admission and routine test results were recorded. After education about MGUS and myeloma, patients chose whether they wished to be informed of new diagnoses. A total of 660 patients were tested and 35 had a paraprotein suggestive of MGUS. The overall rate of MGUS was 5·3%. MGUS prevalence in those aged >50 years was 6·94%, higher than the previously published rate of 3·2% (P < 0·0005). There were higher rates in those with chronic kidney disease (13·75% vs. 4·14%, P = 0·002), heart failure (14% vs. 4·59%, P = 0·012), anaemia (8·96% vs. 3·41%, P = 0·003) or leucocytosis (9·33% vs. 3·04%, P = 0·002). In all, 96% of patients wished to be informed of their screening results. The prevalence of MGUS in emergency hospital admissions is higher than expected based on previous population-based rates. This may suggest a selected population for screening.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  acute medicine; infection; monoclonal gammopathy of undetermined significance; renal dysfunction; screening

Year:  2020        PMID: 31999849     DOI: 10.1111/bjh.16487

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Kidney Biopsy in Patients With Monoclonal Gammopathy: A Multicenter Retrospective Cohort Study.

Authors:  Sheng Nie; Mengyi Wang; Qijun Wan; Yaozhong Kong; Jun Ou; Nan Jia; Xiaodong Zhang; Fan Luo; Xiaoting Liu; Lin Wang; Yue Cao; Ruixuan Chen; Mingpeng Zhao; David Yiu Leung Chan; Guobao Wang
Journal:  Front Med (Lausanne)       Date:  2021-05-24

Review 2.  Epidemiology, Staging, and Management of Multiple Myeloma.

Authors:  Sandeep Anand Padala; Adam Barsouk; Alexander Barsouk; Prashanth Rawla; Anusha Vakiti; Ravindra Kolhe; Vamsi Kota; Germame Hailegiorgis Ajebo
Journal:  Med Sci (Basel)       Date:  2021-01-20

3.  Differences in Hospital, Emergency Room and Outpatient Visits Among Adults With and Without Monoclonal Gammopathy of Undetermined Significance.

Authors:  Maira A Castañeda-Avila; Kate L Lapane; Sharina D Person; Bill M Jesdale; Yanhua Zhou; Kathleen M Mazor; Mara M Epstein
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

4.  Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study.

Authors:  Brian Schwartz; Morten Schou; Frederick L Ruberg; Dane Rucker; Jihoon Choi; Omar Siddiqi; Kevin Monahan; Lars Køber; Gunnar Gislason; Christian Torp-Pedersen; Charlotte Andersson
Journal:  JACC CardioOncol       Date:  2022-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.